Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004;4:277–84. https://doi.org/10.1038/nrc1318.
Article CAS PubMed Google Scholar
Elad S, Yarom N, Zadik Y, Kuten-Shorrer M, Sonis ST. The broadening scope of oral mucositis and oral ulcerative mucosal toxicities of anticancer therapies. CA Cancer J Clin. 2022;72:57–77. https://doi.org/10.3322/caac.21704.
Prowd CW. The Radiation Treatment of Intra-Oral Cancer. Can Med Assoc J. 1933;28:182–4.
CAS PubMed PubMed Central Google Scholar
Farber S, Diamond LK. Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid. N Engl J Med. 1948;238:787–93. https://doi.org/10.1056/NEJM194806032382301.
Article CAS PubMed Google Scholar
Balter AH, Stomatitis. N Engl J Med. 1990;322:704. https://doi.org/10.1056/NEJM199003083221022.
Blijlevens N, et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy–European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol. 2008;26:1519–25. https://doi.org/10.1200/JCO.2007.13.6028.
Article CAS PubMed Google Scholar
Nakagaki M, Kennedy GA, Gavin NC, Clavarino A, Whitfield K. The incidence of severe oral mucositis in patients undergoing different conditioning regimens in haematopoietic stem cell transplantation. Support Care Cancer. 2022;30:9141–9. https://doi.org/10.1007/s00520-022-07328-4.
Article PubMed PubMed Central Google Scholar
Abdalla-Aslan R, et al. Guidance on mucositis assessment from the MASCC Mucositis Study Group and ISOO: an international Delphi study. EClinicalMedicine. 2024;73:102675. https://doi.org/10.1016/j.eclinm.2024.102675.
Article PubMed PubMed Central Google Scholar
Lightfoot MDS, et al. Oral mucositis associated with antibody-drug conjugates in gynecologic oncology: strategies for prevention and treatment. Int J Gynecol Cancer. 2025;35:101997. https://doi.org/10.1016/j.ijgc.2025.101997.
Lo Muzio L, Arena C, Troiano G, Villa A. Oral stomatitis and mTOR inhibitors: A review of current evidence in 20,915 patients. Oral Dis. 2018;24:144–71. https://doi.org/10.1111/odi.12795.
Article CAS PubMed Google Scholar
Zhou S, Kishi N, Alerasool P, Rohs NC. Adverse Event Profile of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer: An Updated Meta-analysis. Target Oncol. 2024;19:547–64. https://doi.org/10.1007/s11523-024-01073-w.
Arena C, Troiano G, De Lillo A, Testa NF, Lo Muzio L. Stomatitis and VEGFR-Tyrosine Kinase Inhibitors (VR-TKIs): A Review of Current Literature in 4369 Patients. Biomed Res Int. 2018. https://doi.org/10.1155/2018/5035217.
Xu Y, Wen N, Sonis ST, Villa A. Oral side effects of immune checkpoint inhibitor therapy (ICIT): An analysis of 4683 patients receiving ICIT for malignancies at Massachusetts General Hospital, Brigham & Women’s Hospital, and the Dana-Farber Cancer Institute, 2011 to 2019. Cancer. 2021;127:1796–804. https://doi.org/10.1002/cncr.33436.
Al-Eryani K, Epstein JB, Monreal AV, Villa A. Orofacial complications from immune checkpoint inhibitors: A retrospective analysis from two academic medical centers. Head Neck. 2024;46:1865–72. https://doi.org/10.1002/hed.27646.
Moore ZR et al. Risk of Unplanned Hospital Encounters in Patients Treated With Radiotherapy for Head and Neck Squamous Cell Carcinoma. J Pain Symptom Manage, 2019, 57, 738–745 e733. https://doi.org/10.1016/j.jpainsymman.2018.12.337
Fahy E, Brooker RC, Fleming JC, Patterson JM. A review of unplanned admissions in head and neck cancer patients undergoing oncological treatment. Support Care Cancer. 2023;31:328. https://doi.org/10.1007/s00520-023-07770-y.
Article PubMed PubMed Central Google Scholar
Bonomi M, Batt K. Supportive Management of Mucositis and Metabolic Derangements in Head and Neck Cancer Patients. Cancers (Basel). 2015;7:1743–57. https://doi.org/10.3390/cancers7030862.
Article CAS PubMed PubMed Central Google Scholar
Vera-Llonch M, Oster G, Hagiwara M, Sonis S. Oral mucositis in patients undergoing radiation treatment for head and neck carcinoma. Cancer. 2006;106:329–36. https://doi.org/10.1002/cncr.21622.
Russo G, Haddad R, Posner M, Machtay M. Radiation treatment breaks and ulcerative mucositis in head and neck cancer. Oncologist. 2008;13:886–98. https://doi.org/10.1634/theoncologist.2008-0024.
Gonzalez Ferreira JA, Olasolo J, Azinovic J, I., Jeremic B. Effect of radiotherapy delay in overall treatment time on local control and survival in head and neck cancer: Review of the literature. Rep Pract Oncol Radiother. 2015;20:328–39. https://doi.org/10.1016/j.rpor.2015.05.010.
Article PubMed PubMed Central Google Scholar
Gharzai LA, et al. Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials. JAMA Otolaryngol Head Neck Surg. 2026;152:144–53. https://doi.org/10.1001/jamaoto.2025.4203.
Article PubMed PubMed Central Google Scholar
Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of autologous hematopoietic stem-cell transplantation following high-dose melphalan conditioning for multiple myeloma. J Support Oncol. 2007;5:231–5.
Sonis ST, et al. Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol. 2001;19:2201–5. https://doi.org/10.1200/JCO.2001.19.8.2201.
Article CAS PubMed Google Scholar
Blijlevens NMA, de Mooij CEM. Mucositis and Infection in Hematology Patients. Int J Mol Sci. 2023;24. https://doi.org/10.3390/ijms24119592.
Satheeshkumar PS, Blijlevens N, Sonis ST. Application of big data analyses to compare the impact of oral and gastrointestinal mucositis on risks and outcomes of febrile neutropenia and septicemia among patients hospitalized for the treatment of leukemia or multiple myeloma. Support Care Cancer. 2023;31:199. https://doi.org/10.1007/s00520-023-07654-1.
Carlotto A, Hogsett VL, Maiorini EM, Razulis JG, Sonis ST. The economic burden of toxicities associated with cancer treatment: review of the literature and analysis of nausea and vomiting, diarrhoea, oral mucositis and fatigue. PharmacoEconomics. 2013;31:753–66. https://doi.org/10.1007/s40273-013-0081-2.
Elad S, Zadik Y. Chronic oral mucositis after radiotherapy to the head and neck: a new insight. Support Care Cancer. 2016;24:4825–30. https://doi.org/10.1007/s00520-016-3337-5.
Mohammed AI, et al. Assessment of Oxidative Stress-Induced Oral Epithelial Toxicity. Biomolecules. 2023;13. https://doi.org/10.3390/biom13081239.
Sonis ST. New thoughts on the initiation of mucositis. Oral Dis. 2010;16:597–600. https://doi.org/10.1111/j.1601-0825.2010.01681.x.
Article CAS PubMed Google Scholar
Stringer AM, et al. Updated perspectives on the contribution of the microbiome to the pathogenesis of mucositis using the MASCC/ISOO framework. Support Care Cancer. 2024;32:558. https://doi.org/10.1007/s00520-024-08752-4.
Article PubMed PubMed Central Google Scholar
Raber-Durlacher JE, et al. Oral mucositis in patients treated with chemotherapy for solid tumors: a retrospective analysis of 150 cases. Support Care Cancer. 2000;8:366–71. https://doi.org/10.1007/s005200050004.
Article CAS PubMed Google Scholar
Jones JA, et al. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006;14:505–15. https://doi.org/10.1007/s00520-006-0055-4.
Saito Y, Takekuma Y, Takahashi M, Oshino T, Sugawara M. Association of oral mucositis induced by anthracycline-cyclophosphamide and subsequent docetaxel treatment for perioperative breast cancer. Support Care Cancer. 2024;32:513. https://doi.org/10.1007/s00520-024-08733-7.
Comments (0)